Ireland
--:--IST
Latest
Airmid Éireann 1.4 Puts Irish Pharma Data in Global Context Northern Ireland Phone Switch-Off: Check Medical Devices Irish Medtech Calls for MDR and IVDR Reform at Galway Event Clonmel Healthcare Launches Mabelle Menocare Supplements HealthSpan Partners to Acquire Irish GP Group Centric Health Outpatient Waiting List Reaches 692,524, Up 10.5% in a Year Airmid Éireann 1.4 Puts Irish Pharma Data in Global Context Northern Ireland Phone Switch-Off: Check Medical Devices Irish Medtech Calls for MDR and IVDR Reform at Galway Event Clonmel Healthcare Launches Mabelle Menocare Supplements HealthSpan Partners to Acquire Irish GP Group Centric Health Outpatient Waiting List Reaches 692,524, Up 10.5% in a Year
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nantes
Clinical trial register · France

Clinical Trials in Nantes, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC
9697
Studies in scope
all four open statuses
6025
Recruiting now
open to new participants
1033
Lead sponsors
across recruiting studies
Top sites
Paris 68 Marseille 36 Bordeaux 35 Montpellier 32 Lille 31
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Nantes University Hospital176 Janssen Research & Development, LLC35 AstraZeneca27 Novartis Pharmaceuticals25 Sanofi17 Clear sponsor filter
Site location
Paris68 Marseille36 Bordeaux35 Montpellier32 Lille31
All 73 locations
Target enrolment
to

Trials with a site in Nantes

25 of 9697 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
DrugAtrasentan
Novartis Pharmaceuticals
Phase 3
28
Bron, Nantes, Toulouse
2026-08-06
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Caen, Créteil, Lille, Marseille, Nantes, Paris, Rennes, Toulouse
2026-06-03
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Bron, Chambray-lès-Tours, Compiègne, Grenoble, Le Coudray, Nantes, Paris, Toulouse
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Créteil, Lille, Nantes
2026-01-13
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
Bordeaux, Clermont-Ferrand, Nantes, Villejuif
2025-12-05
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Chambray-lès-Tours, Montpellier, Nantes, Pessac, Poitiers
2025-10-03
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Bron, Clichy, Montpellier, Nantes, Pessac, Toulouse
2025-05-30
Recruiting
Novartis Pharmaceuticals
Phase 2
20
Bordeaux, Lille, Lyon, Nantes, Paris, Vandœuvre-lès-Nancy
2025-02-18
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Marseille, Nantes, Paris
2024-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Bordeaux, Clermont-Ferrand, Marseille, Montpellier, Nantes, Paris, Strasbourg, Toulouse
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 1
31
Nantes
2024-07-29
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Toulon, Brest, Cholet, Colmar, Dijon, Le Mans, Nantes, Reims
2024-06-28
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Grenoble, Montpellier, Nantes, Paris, Pierre-Bénite, Rouen, Toulouse
2023-12-07
Active, closed
Novartis Pharmaceuticals
Phase 1
33
Dijon, Clermont-Ferrand, Lyon, Nantes, Saint-Herblain, Vandœuvre-lès-Nancy
2023-11-07
Active, closed
Novartis Pharmaceuticals
Phase 1
71
Grenoble, Nantes, Paris
2023-05-08
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Créteil, Lille, Nantes, Nice
2022-12-30
Active, closed
Novartis Pharmaceuticals
Phase 3
568
Bordeaux, Caen, Clermont-Ferrand, Lille, Lyon, Marseille, Nantes, Nice
2022-11-21
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Bordeaux, Lyon, Marseille, Nantes, Paris, Vandœuvre-lès-Nancy
2022-08-30
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Bordeaux, Lyon, Nantes, Paris
2021-10-06
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Lille, Nantes, Nice, Paris, Toulouse
2021-07-27
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Bordeaux, Clermont-Ferrand, Lyon, Montpellier, Nantes, Paris, Strasbourg, Vandœuvre-lès-Nancy
2021-06-09
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bordeaux, Lille, Lyon, Nantes, Saint-Herblain, Strasbourg, Villejuif
2019-09-18
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Lille, Montpellier, Nantes, Nice, Nîmes, Paris, Strasbourg
2018-12-28
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Lyon, Nantes, Paris, Villejuif
2018-01-26
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Nantes, Paris, Pessac, Pierre-Bénite, Strasbourg, Villejuif
2015-11-02
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 October 2026. https://priyalifescience.com/clinical-trials-france/city/nantes

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies with a site in Nantes that also match the filters currently applied.

How many clinical trials are recruiting in Nantes?

12 of the 25 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nantes), 25 studies
PhaseStudiesRecruitingShare
Phase 315660%
Phase 13012%
Phase 1/23312%
Phase 2218%
Phase 4228%

Most active sponsors

Lead sponsors with the most studies (Nantes)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals2512
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.